Literature DB >> 7238434

Ictal effects of anticonvulsant medication withdrawal in epileptic patients.

S S Spencer, D D Spencer, P D Williamson, R H Mattson.   

Abstract

Medication withdrawal is used in selected instances to precipitate seizures during evaluation of epileptic patients. Whether such medication manipulation can alter electrical seizure onset or clinical seizure type is not known. Information regarding the effects of anticonvulsant withdrawal on depth EEG onset and clinical manifestations of seizures was reviewed in 25 patients with partial complex seizures in whom intracranial electrodes were implanted. For the purposes of this study, the withdrawal period was defined as the time after abrupt cessation of medication between one and five half-lives of the drug and the base-line state as all other times. Ten patients were withdrawn from carbamazepine, 6 from phenobarbital, 2 from phenytoin, and 3 from primidone. Overall effects of anticonvulsant withdrawal in 18 patients and 21 instances of withdrawal with a total of 89 withdrawal and 71 base-line seizures were notable. Focal electrical onset and typical clinical seizure type during withdrawal were entirely consistent with electrical and/or clinical characteristics of seizures occurring during the base-line state in 13 instances. "New" clinical and/or electrical seizure types occurred during withdrawal only in a number of patients in whom bilateral or multifocal seizure onset was confirmed electrographically outside of the withdrawal period. In only 1 patient did withdrawal produce atypical clinical and electrical seizures when the base-line state showed a clinically typical seizure of clear-cut localized onset. After surgery this patient was shown to have unequivocal multifocal seizure onset. Thus, for purposes of localizing single epileptic foci, information obtained during the anticonvulsant withdrawal period provided no misleading information in this group of patients, while condensing the time needed for evaluation.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7238434     DOI: 10.1111/j.1528-1157.1981.tb04113.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  5 in total

1.  Does early postoperative drug regimen impact seizure control in patients undergoing temporal lobe resections?

Authors:  Barbara Schmeiser; Bernhard J Steinhoff; Andreas Schulze-Bonhage
Journal:  J Neurol       Date:  2018-01-06       Impact factor: 4.849

2.  Utility of stereoelectroencephalography in preoperative assessment of temporal lobe epilepsy.

Authors:  C D Binnie; R D Elwes; C E Polkey; A Volans
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-01       Impact factor: 10.154

3.  Multiple mechanisms shape the relationship between pathway and duration of focal seizures.

Authors:  Gabrielle M Schroeder; Fahmida A Chowdhury; Mark J Cook; Beate Diehl; John S Duncan; Philippa J Karoly; Peter N Taylor; Yujiang Wang
Journal:  Brain Commun       Date:  2022-07-06

4.  Seizure pathways change on circadian and slower timescales in individual patients with focal epilepsy.

Authors:  Gabrielle M Schroeder; Beate Diehl; Fahmida A Chowdhury; John S Duncan; Jane de Tisi; Andrew J Trevelyan; Rob Forsyth; Andrew Jackson; Peter N Taylor; Yujiang Wang
Journal:  Proc Natl Acad Sci U S A       Date:  2020-05-04       Impact factor: 11.205

5.  Mesial temporal resection following long-term ambulatory intracranial EEG monitoring with a direct brain-responsive neurostimulation system.

Authors:  Lawrence J Hirsch; Emily A Mirro; Vicenta Salanova; Thomas C Witt; Cornelia N Drees; Mesha-Gay Brown; Ricky W Lee; Toni L Sadler; Elizabeth A Felton; Paul Rutecki; Hae Won Shin; Eldad Hadar; Manu Hegde; Vikram R Rao; Lilit Mnatsakanyan; Deepak S Madhavan; Tarek J Zakaria; Anli A Liu; Christianne N Heck; Janet E Greenwood; Jeffrey K Bigelow; Dileep R Nair; Andreas V Alexopoulos; Michael Mackow; Jonathan C Edwards; Nadia Sotudeh; Ruben I Kuzniecky; Ryder P Gwinn; Michael J Doherty; Eric B Geller; Martha J Morrell
Journal:  Epilepsia       Date:  2020-02-18       Impact factor: 5.864

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.